Sodium tanshinone IIA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats

American Journal of Respiratory Cell and Molecular Biology

Volumn 48, Issue 1, 2013, Pages 125-134

  Wang, Jian ^a,b   Jiang, Qian ^a   Wan, Limei ^a   Yang, Kai ^a,b   Zhang, Yi ^a,b   Chen, Yuqin ^a   Wang, Elizabeth ^c   Lai, Ning ^a,b   Zhao, Lei ^a   Jiang, Hua ^a   Sun, Yueqian ^d   Zhong, Nanshan ^a   Ran, Pixin ^a   Lu, Wenju ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Pulmonary hypertension; SOCE; STS; TRPC

Indexed keywords

ANTIHYPERTENSIVE AGENT; FURA 2; MANGANESE; MESSENGER RNA; MONOCROTALINE; TANSHINONE IIA; TANSHINONE IIA SULFONIC ACID; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY MUSCLE; ARTICLE; CALCIUM CELL LEVEL; CELL HYPOXIA; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CHRONICALLY HYPOXIC PULMONARY HYPERTENSION; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; EX VIVO STUDY; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; LUNG BLOOD VESSEL; NONHUMAN; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE;

ANIMALS; ANOXIA; CALCIUM; CALCIUM CHANNELS; CELL MOVEMENT; CELL PROLIFERATION; DRUGS, CHINESE HERBAL; HEMODYNAMICS; HYPERTENSION, PULMONARY; MALE; MUSCLE, SMOOTH, VASCULAR; PHENANTHRENES; PHYTOTHERAPY; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; SALVIA MILTIORRHIZA; TRANSIENT RECEPTOR POTENTIAL CHANNELS; TRPC CATION CHANNELS;

RATTUS; SALVIA MILTIORRHIZA;

EID: 84871907539     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2012-0071OC     Document Type: Article

References (60)

1. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34:1219-1263.
2. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation 2010;122:164-172.
3. Kane GC, Maradit-Kremers H, Slusser JP, Scott CG, Frantz RP, McGoon MD. Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. Chest 2011;139:1285-1293.
4. Thenappan T, Glassner C, Gomberg-Maitland M. Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension. Chest 2012;141:642-650.
5. Clements PJ, Tan M, McLaughlin VV, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ, Langer A. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis 2012;71:249-252.
6. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galie N. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(Suppl)S78-S84.
7. Kramer MR. [Combination treatment in pulmonary arterial hypertension] (in Hebrew). Harefuah 2011;150:383-388, 417.
8. Levinson AT, Klinger JR. Combination therapy for the treatment of pulmonary arterial hypertension. Ther Adv Respir Dis 2011;5:419-430.
9. Abraham T, Wu G, Vastey F, Rapp J, Saad N, Balmir E. Role of combination therapy in the treatment of pulmonary arterial hypertension. Pharmacotherapy 2010;30:390-404.
10. Kahler CM. [Combination therapy for the treatment of pulmonary arterial hypertension] (in German). Dtsch Med Wochenschr 2009;134:S181-S182.
11. Benza RL, Rayburn BK, Tallaj JA, Pamboukian SV, Bourge RC. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan. Chest 2008;134:139-145. (Pubitemid 352008775)
12. Jiang WD, Yu YZ, Liu WW, Chen YH, Wang YP, Huang TC. [Effects of sodium tanshinone II-A sulfonate and propranolol on coronary collaterals in acutely infarcted dogs] (in Chinese). Zhongguo Yao Li Xue Bao 1981;2:29-33.
13. Liu J, Morton J, Miedzyblocki M, Lee TF, Bigam DL, Fok TF, Chen C, Lee SK, Davidge ST, Cheung PY. Sodium tanshinone IIA sulfonate increased intestinal hemodynamics without systemic circulatory changes in healthy newborn piglets. Am J Physiol Heart Circ Physiol 2009;297:H1217-H1224.
14. Zhou L, Zuo Z, Chow MS. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 2005;45:1345-1359. (Pubitemid 41643896)
15. Feng J, Zheng Z. Effect of sodium tanshinone II A sulfonate on cardiac myocyte hypertrophy and its underlying mechanism. Chin J Integr Med 2008;14:197-201.
16. Zhou D, Liang Q, He X, Zhan C. Changes of c-Fos and c-jun mRNA expression in angiotensin II-induced cardiomyocyte hypertrophy and effects of sodium tanshinone IIA sulfonate. J Huazhong Univ Sci Technolog Med Sci 2008;28:531-534.
17. Yang Y, Cai F, Li PY, Li ML, Chen J, Chen GL, Liu ZF, Zeng XR. Activation of high conductance Ca(2+) -activated K(+) channels by sodium tanshinone II-A sulfonate (ds-201) in porcine coronary artery smooth muscle cells. Eur J Pharmacol 2008;598:9-15.
18. Gao S, Liu Z, Li H, Little PJ, Liu P, Xu S. Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis 2012;220:3-10.
19. Huang YF, Liu ML, Dong MQ, Yang WC, Zhang B, Luan LL, Dong HY, Xu M, Wang YX, Liu LL, et al. Effects of sodium tanshinone II A sulphonate on hypoxic pulmonary hypertension in rats in vivo and on Kv2.1 expression in pulmonary artery smooth muscle cells in vitro. J Ethnopharmacol 2009;125:436-443.
20. Wang J, Dong MQ, Liu ML, Xu DQ, Luo Y, Zhang B, Liu LL, Xu M, Zhao PT, Gao YQ, et al. Tanshinone IIA modulates pulmonary vascular response to agonist and hypoxia primarily via inhibiting Ca2+ influx and release in normal and hypoxic pulmonary hypertension rats. Eur J Pharmacol 2010;640:129-138.
21. Leach RM, Treacher DF. Clinical aspects of hypoxic pulmonary vasoconstriction. Exp Physiol 1995;80:865-875.
22. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 2006;99:675-691. (Pubitemid 44498302)
23. Hanasato N, Oka M, Muramatsu M, Nishino M, Adachi H, Fukuchi Y. E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats. Am J Physiol 1999;277:L225-L232. (Pubitemid 29415078)
24. Oka M, Morris KG, McMurtry IF. NIP-121 is more effective than Nifedipine in acutely reversing chronic pulmonary hypertension. J Appl Physiol 1993;75:1075-1080. (Pubitemid 23289593)
25. Muramatsu M, Oka M, Morio Y, Soma S, Takahashi H, Fukuchi Y. Chronic hypoxia augments endothelin-B receptor-mediated vasodilation in isolated perfused rat lungs. Am J Physiol 1999;276:L358-L364. (Pubitemid 29102278)
26. Liu X, Singh BB, Ambudkar IS. TRPC1 is required for functional store-operated Ca2 1 channels: role of acidic amino acid residues in the s5-s6 region. J Biol Chem 2003;278:11337-11343. (Pubitemid 36792691)
27. Wang J, Shimoda LA, Sylvester JT. Capacitative calcium entry and TRPC channel proteins are expressed in rat distal pulmonary arterial smooth muscle. Am J Physiol Lung Cell Mol Physiol 2004;286:L848-L858. (Pubitemid 38365072)
28. Wang J, Semenza G, Sylvester JT, Shimoda LA. Hif-1 regulates hypoxic-induction of canonical transient receptor potential (TRPC) channels in pulmonary arterial smooth muscle cells [abstract]. FASEB J 2005;19:A1278.
29. Wang J, Weigand L, Lu W, Sylvester JT, Semenza GL, Shimoda LA. Hypoxia inducible factor 1 mediates hypoxia-induced TRPC expression and elevated intracellular Ca2+ in pulmonary arterial smooth muscle cells. Circ Res 2006;98:1528-1537. (Pubitemid 44297076)
30. Lu W, Ran P, Zhang D, Peng G, Li B, Zhong N, Wang J. Sildenafil inhibits chronically hypoxic upregulation of canonical transient receptor potential expression in rat pulmonary arterial smooth muscle. Am J Physiol Cell Physiol 2009;298:C114-C123.
31. Lu W, Wang J, Shimoda LA, Sylvester JT. Differences in STIM1 and TRPC expression in proximal and distal pulmonary arterial smooth muscle are associated with differences in Ca2+ responses to hypoxia. Am J Physiol Lung Cell Mol Physiol 2008;295:L104-L113.
32. Shimoda LA, Sham JS, Sylvester JT. Altered pulmonary vasoreactivity in the chronically hypoxic lung. Physiol Res 2000;49:549-560.
33. Lu W, Ran P, Zhang D, Lai N, Zhong N, Wang J. Bone morphogenetic protein 4 enhances canonical transient receptor potential expression, store-operated Ca2+ entry, and basal [Ca2+]i in rat distal pulmonary arterial smooth muscle cells. Am J Physiol Cell Physiol 2010;299: C1370-C1378.
34. Lu W, Wang J, Peng G, Shimoda LA, Sylvester JT. Knockdown of stromal interaction molecule 1 attenuates store-operated Ca2+ entry and Ca2+ responses to acute hypoxia in pulmonary arterial smooth muscle. Am J Physiol Lung Cell Mol Physiol 2009;297:L17-L25.
35. Lu HZ, Hu JG. Expression of bone morphogenetic proteins-2/4 in neural stem cells and their lineages. Acta Neurobiol Exp (Warsz) 2009;69:441-447.
36. Nong Z, Stassen JM, Moons L, Collen D, Janssens S. Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling. Circulation 1996;94:1941-1947. (Pubitemid 26349309)
37. Adamy C, Oliviero P, Eddahibi S, Rappaport L, Samuel JL, Teiger E, Chassagne C. Cardiac modulations of ANG II receptor expression in rats with hypoxic pulmonary hypertension. Am J Physiol Heart Circ Physiol 2002;283:H733-H740. (Pubitemid 34790869)
38. Sun D, Shen M, Li J, Li W, Zhang Y, Zhao L, Zhang Z, Yuan Y, Wang H, Cao F. Cardioprotective effects of tanshinone IIA pretreatment via kinin b2 receptor-AKT-GSK-3beta dependent pathway in experimental diabetic cardiomyopathy. Cardiovasc Diabetol 2011;10:4.
39. Wang P, Wu X, Bao Y, Fang J, Zhou S, Gao J, Pi R, Mou YG, Liu P. Tanshinone IIA prevents cardiac remodeling through attenuating NAD(P)H oxidase-derived reactive oxygen species production in hypertensive rats. Pharmazie 2011;66:517-524.
40. Xu W, Yang J, Wu LM. Cardioprotective effects of tanshinone IIA on myocardial ischemia injury in rats. Pharmazie 2009;64:332-336.
41. K+ channel-mediated relaxation. Am J Physiol 1992;263:L88-L94.
42. Mandegar M, Fung YC, Huang W, Remillard CV, Rubin LJ, Yuan JX. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res 2004;68:75-103. (Pubitemid 39093882)
43. Stanbrook HS, Morris KG, McMurtry IF. Prevention and reversal of hypoxic pulmonary hypertension by calcium antagonists. Am Rev Respir Dis 1984;130:81-85. (Pubitemid 14092986)
44. Platoshyn O, Golovina VA, Bailey CL, Limsuwan A, Krick S, Juhaszova M, Seiden JE, Rubin LJ, Yuan JX. Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation. Am J Physiol Cell Physiol 2000;279:C1540-C1549.
45. + channel alpha subunits in pulmonary artery smooth muscle cells. J Clin Invest 1997;100:2347-2353.
46. Liu JQ, Sham JS, Shimoda LA, Kuppusamy P, Sylvester JT. Hypoxic constriction and reactive oxygen species in porcine distal pulmonary arteries. Am J Physiol Lung Cell Mol Physiol 2003;285:L322-L333. (Pubitemid 36909448)
47. Wang J, Weigand L, Wang W, Sylvester JT, Shimoda LA. Chronic hypoxia inhibits Kv channel gene expression in rat distal pulmonary artery. Am J Physiol Lung Cell Mol Physiol 2005;288:L1049-L1058. (Pubitemid 40695430)
48. 2+ entry. Am J Physiol Lung Cell Mol Physiol 2005;288:L1059-L1069.
49. Cook B, Minke B. Trp and calcium stores in Drosophila phototransduction. Cell Calcium 1999;25:161-171. (Pubitemid 29141420)
50. Liu XR, Zhang MF, Yang N, Liu Q, Wang RX, Cao YN, Yang XR, Sham JS, Lin MJ. Enhanced store-operated Ca2+ entry and TRPC channel expression in pulmonary arteries of monocrotaline-induced pulmonary hypertensive rats. Am J Physiol Cell Physiol 2012;302:C77-C87.
51. Chen TH, Hsu YT, Chen CH, Kao SH, Lee HM. Tanshinone IIA from Salvia miltiorrhiza induces heme oxygenase-1 expression and inhibits lipopolysaccharide-induced nitric oxide expression in Raw 264.7 cells. Mitochondrion 2007;7:101-105. (Pubitemid 46351958)
52. Qi YY, Xiao L, Zhang LD, Song SH, Mei Y, Chen T, Tang JM, Liu F, Ding GS, Shi YZ, et al. Tanshinone IIA pretreatment attenuates hepatic ischemia-reperfusion. Front Biosci 2012;4:1303-1313. (Elite Ed).
53. Chan P, Liu JC, Lin LJ, Chen PY, Cheng TH, Lin JG, Hong HJ. Tanshinone iia inhibits angiotensin II-induced cell proliferation in rat cardiac fibroblasts. Am J Chin Med 2011;39:381-394.
54. Zhang HS, Wang SQ. Nrf2 is involved in the effect of tanshinone IIA on intracellular redox status in human aortic smooth muscle cells. Biochem Pharmacol 2007;73:1358-1366.
55. Kim EY, Anderson M, Dryer SE. Insulin increases surface expression of TRPC6 channels in podocytes: role of NADPH oxidases and reactive oxygen species. Am J Physiol Renal Physiol 2012;302:F298-F307.
56. Ding Y, Winters A, Ding M, Graham S, Akopova I, Muallem S, Wang Y, Hong JH, Gryczynski Z, Yang SH, et al. Reactive oxygen species-mediated TRPC6 protein activation in vascular myocytes, a mechanism for vasoconstrictor-regulated vascular tone. J Biol Chem 2011;286:31799-31809.
57. Graham S, Gorin Y, Abboud HE, Ding M, Lee DY, Shi H, Ding Y, Ma R. Abundance of TRPC6 protein in glomerular mesangial cells is decreased by ROS and PKC in diabetes. Am J Physiol Cell Physiol 2011;301:C304-C315.
58. Rathore R, Zheng YM, Niu CF, Liu QH, Korde A, Ho YS, Wang YX. Hypoxia activates NADPH oxidase to increase [ROS]i and [Ca2+]i through the mitochondrial ROS-PKCepsilon signaling axis in pulmonary artery smooth muscle cells. Free Radic Biol Med 2008;45:1223-1231.
59. Wang S, Song P, Zou MH. Amp-activated protein kinase, stress responses and cardiovascular diseases. Clin Sci (Lond) 2012;122:555-573.
60. Pan C, Lou L, Huo Y, Singh G, Chen M, Zhang D, Wu A, Zhao M, Wang S, Li J. Salvianolic acid b and tanshinone IIA attenuate myocardial ischemia injury in mice by no production through multiple pathways. Ther Adv Cardiovasc Dis 2011;5:99-111.